Maze Therapeutics (MAZE) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 8, 2026, with voting on director elections and auditor ratification.

• The company is a clinical-stage biopharmaceutical firm focused on precision medicines for kidney and metabolic diseases, leveraging its Compass platform for drug discovery and development.

• The board recommends voting for all director nominees and for the ratification of Ernst & Young LLP as the independent auditor.

Voting matters and shareholder proposals

• Stockholders will vote to elect Jason Coloma, Ph.D., and Neil Kumar, Ph.D., as Class I directors for terms expiring at the 2029 annual meeting.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, is on the agenda.

• No other matters are currently expected to be brought before the meeting.

Board of directors and corporate governance

• The board is classified into three staggered classes, with only one class up for election each year.

• A majority of directors are independent; all audit and compensation committee members are independent.

• The board conducts annual self-evaluations and maintains open communication with management.

• Committees include audit, compensation, nominating and corporate governance, and advisory research and development.

• The board structure separates the roles of chairman and CEO.